Showing results (1-10 of 102) with videos related to
Sort By:
Pageof 11
JCI Insight|March 15, 2017
Setting the target for pemphigus vulgaris therapyChristoph T Ellebrecht, Aimee S PayneThe Journal of Investigative Dermatology|March 21, 2014
Plakophilins, desmogleins, and pemphigus: the tail wagging the dogChristoph T Ellebrecht, Aimee S PayneThe Journal of Investigative Dermatology|November 10, 2021
Pemphigus and Pemphigoid: From Disease Mechanisms to Druggable PathwaysChristoph T Ellebrecht, Damian Maseda, Aimee S PayneCurrent Opinion in Immunology|September 30, 2019
On the mark: genetically engineered immunotherapies for autoimmunityChristoph T Ellebrecht, Daniel K Lundgren, Aimee S PayneCytokine|December 4, 2014
The dual nature of interleukin-10 in pemphigus vulgarisMichael Jeffrey Cho, Christoph T Ellebrecht, Aimee S PayneJCI Insight|May 5, 2017
Stat3 regulates desmoglein 3 transcription in epithelial keratinocytesXuming Mao, Michael Jeffrey T Cho, Christoph T Ellebrecht, et al.Nature Reviews. Disease Primers|May 12, 2018
Correction: Paraneoplastic autoimmune multiorgan syndrome and paraneoplastic pemphigus describe the same spectrum of disease pathologyAimee S Payne, Michael Kasperkiewicz, Christoph T Ellebrecht, et al.Nature Reviews. Disease Primers|May 12, 2017
PemphigusMichael Kasperkiewicz, Christoph T Ellebrecht, Hayato Takahashi, et al.Cell Reports|August 30, 2018
Autoreactive IgG and IgA B Cells Evolve through Distinct Subclass Switch Pathways in the Autoimmune Disease Pemphigus VulgarisChristoph T Ellebrecht, Eric M Mukherjee, Qi Zheng, et al.JAMA Dermatology|August 19, 2014
Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgarisChristoph T Ellebrecht, Eun J Choi, David M Allman, et al.Pageof 11